BioGaia AB (publ)
Research BioGaia AB (publ) (BIOG-B) on Bullrun: valuation model: 4.1% undervalued, market cap SEK 12.02B, P/E 36.2, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIOG-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Valuation signal4.1% undervalued
- Market capSEK 12.02B
- P/E36.2
- Dividend yield1.4%
- Financial periodFY2022
- RevenueSEK 1.10B
- Revenue growth40.6%
- Net incomeSEK 373.77M
- Free cash flowSEK 301.03M
- Gross margin72.6%
Valuation Snapshot
Bullrun's latest valuation model marks BioGaia AB (publ) as 4.1% undervalued; latest market cap is SEK 12.02B; P/E is 36.2; dividend yield is 1.4%.
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula.
Frequently asked questions
Is BioGaia AB (publ) overvalued or undervalued?
Bullrun's valuation model currently marks BioGaia AB (publ) as 4.1% undervalued.
What is BioGaia AB (publ)'s market cap?
BioGaia AB (publ)'s market capitalization is SEK 12.02B.
What is BioGaia AB (publ)'s P/E ratio?
BioGaia AB (publ)'s price-to-earnings (P/E) ratio is 36.2.
Does BioGaia AB (publ) pay a dividend?
BioGaia AB (publ) has a dividend yield of 1.4%.
What does BioGaia AB (publ) do?
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments.